LONG TERM DRUG SURVIVAL FOR BIOSIMILAR SB4 ETANERCEPT IN RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS PATIENTS WITH A NON-MEDICAL SWITCH FROM ETANERCEPT REFERENCE DRUG

被引：0
|
作者：
Haugeberg, Glenn [1 ]
Fevang, Bjorg Tilde Svanes [2 ]
Bakland, Gunnstein [3 ]
Rodevand, Erik [4 ]
Diamantopoulos, Andreas [5 ]
机构：
[1] Sorlandet Hosp Kristiansand, Rheumatol, Kristiansand, Norway
[2] Haukeland Hosp, Rheumatol, Bergen, Norway
[3] Univ Hosp North Norway HF, Rheumatol, Tromso, Norway
[4] St Olavs Hosp HF, Rheumatol, Trondheim, Norway
[5] Martina Hansens Hosp, Rheumatol, Baerum, Norway
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2019年 / 78卷
关键词：
D O I：
10.1136/annrheumdis-2019-eular.7387
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
FRI0094
引用
收藏
页码：710 / 711
页数：2
相关论文
共 50 条
  • [41] Non-trough serum drug levels of adalimumab and etanercept are associated with response in patients with psoriatic arthritis
    Curry, Philippa D. K.
    Hum, Ryan M.
    Morris, Andrew P.
    Jani, Meghna
    Chinoy, Hector
    Barton, Anne
    Bluett, James
    RHEUMATOLOGY, 2024,
  • [42] A PHASE III RANDOMISED, DOUBLE-BLIND CLINICAL STUDY COMPARING SB4, AN ETANERCEPT BIOSIMILAR, WITH ETANERCEPT REFERENCE PRODUCT (ENBREL®) IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPY (24-WEEK RESULTS)
    Vencovsky, J.
    Sylwestrzak, A.
    Leszczynski, P.
    Porawska, W.
    Baranauskaite, A.
    Tseluyko, V.
    Zhdan, V.
    Stasiuk, B.
    Milasiene, R.
    Rodriguez, A. A. Barrera
    Cheong, S. Y.
    Ghil, J.
    Emery, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 467 - 468
  • [43] A Phase III, Randomized, Double-Blind Clinical Study Comparing SB4, an Etanercept Biosimilar, with Etanercept Reference Product (Enbrel®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (52-week Results)
    Vencovsky, Jiri
    Sylwestrzak, Anna
    Leszczynski, Piotr
    Porawska, Wieslawa
    Baranauskaite, Asta
    Tseluyko, Vira
    Zhdan, Vyacheslav
    Stasiuk, Barbara
    Milasiene, Roma
    Barrera Rodriguez, Aaron Alejandro
    Cheong, Soo Yeon
    Ghil, Jeehoon
    Emery, Paul
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [44] A Non-Interventional Prospective Observational Study of Treatment with Etanercept Biosimilar (SB4) in Rheumatoid Arthritis in Real Life Clinical Practice; Interim Analysis of the 'BENEFICIAL' Study
    Athanassiou, Panagiotis
    Bounas, Andreas
    Boumpas, Dimitrios
    Sidiropoulos, Prodromos
    Tsalapaki, Christina
    Garyfallos, Alexandros
    Grika, Eleftheria
    Voulgari, Paraskevi
    Kekki, Angeliki
    Anagnostopoulos, Zafeirios
    Karachalios, Georgios
    Antonakopoulos, Nikos
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 1749 - 1752
  • [45] The drug survival of adalimumab compared to etanercept and infliximab in treatment of patients with rheumatoid arthritis in daily clinical practice
    Kievit, W.
    Fransen, J.
    Kupper, H. H.
    Van de Laar, M. A. F. J.
    De Rooij, D. J. R. A.
    De Gendt, C. M.
    Jansen, T. L.
    Ronday, K. H.
    Bruse, H. L. C.
    Moolenburgh, J. D.
    Janson, M.
    Van Oijen, P. C. M.
    Adang, E. M.
    Van Riel, P. L. C. M.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 325 - 325
  • [46] Response to: 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching' by Cantini and Benucci
    Glintborg, Bente
    Loft, Anne Gitte
    Omerovic, Emina
    Hendricks, Oliver
    Linauskas, Asta
    Espesen, Jakob
    Danebod, Kamilla
    Jensen, Dorte Vendelbo
    Nordin, Henrik
    Dalgaard, Emil Barner
    Chrysidis, Stavros
    Kristensen, Salome
    Raun, Johnny Lillelund
    Lindegaard, Hanne
    Manilo, Natalia
    Jakobsen, Susanne Hojmark
    Hansen, Inger Marie Jensen
    Pedersen, Dorte Dalsgaard
    Sorensen, Inge Juul
    Andersen, Lis Smedegaard
    Grydehoj, Jolanta
    Mehnert, Frank
    Krogh, Niels Steen
    Hetland, Merete Lund
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (02)
  • [47] DRUG SURVIVAL ON FIRST TNF INHIBITORS IN PATIENTS WITH PSORIATIC ARTHRITIS: COMPARISON ACROSS ETANERCEPT, ADALIMUMAB, GOLIMUMAB AND INFLIXIMAB
    Garcia-Porrua, C.
    Maceiras-Pan, F.
    Fernandez-Dominguez, L.
    Mosquera-Martinez, J. A.
    Correa-Rey, B.
    Pombo-Suarez, M.
    Pinto-Tasende, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1031 - 1031
  • [48] One-year treatment retention after a nationwide non-medical switch from originator to biosimilar etanercept in 2061 patients with inflammatory arthritis followed in the DANBIO registry
    Glintborg, B.
    Sorensen, I. J.
    Omerovic, E.
    Mehnert, F.
    Manilo, N.
    Danebod, K.
    Jensen, D. V.
    Nordin, H.
    Hendricks, O.
    Loft, A. G.
    Chrysidis, S.
    Andersen, B. L.
    Raun, J. L.
    Lindegaard, H.
    Espesen, J.
    Jakobsen, S. H.
    Hansen, I. J.
    Dalgaard, E. B.
    Pedersen, D. D.
    Kristensen, S.
    Linauskas, A.
    Andersen, L. S.
    Grydehoj, J.
    Krogh, N. S.
    Hetland, M. L.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2018, 47 : 57 - 58
  • [49] Etanercept biosimilar SB4 in the treatment of plaque-type psoriasis and psoriatic arthritis: a single-centre, observational, retrospective, real-life study
    Giunta, A.
    Manfreda, V.
    Esposito, M.
    Del Duca, E.
    Bianchi, L.
    BRITISH JOURNAL OF DERMATOLOGY, 2019, 181 (05) : 1078 - 1079
  • [50] DRUG SURVIVAL OF BIOLOGICS AND NOVEL IMMUNOMODULATORS FOR RHEUMATOID ARTHRITIS, AXIAL SPONDYLOARTHRITIS, PSORIATIC ARTHRITIS, AND PSORIASIS - A NATIONWIDE COHORT STUDY FROM THE DANBIO AND DERMBIO REGISTRIES
    Egeberg, A.
    Rosenoe, N. Lippert
    Aagaard, D.
    Lorup, E.
    Nymand, L.
    Kristensen, E.
    Thyssen, J.
    Thomsen, S. F.
    Cordtz, R. L.
    Loft, N.
    Skov, L.
    Bryld, L. E.
    Rasmussen, M.
    Hojgaard, P.
    Kristensen, S.
    Dreyer, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 256 - 257
12345